13:56 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting miR-204 to treat osteoarthritis

DISEASE CATEGORY: Autoimmune disease INDICATION: Osteoarthritis Patient sample and mouse studies suggest inhibiting miR-204 could help treat osteoarthritis. In patients, levels of miR-204 were higher in damaged cartilage than in undamaged cartilage. In a mouse...
22:51 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Neuroendocrine tumors Patient sample, cell culture and mouse studies suggest agents that mimic or promote expression of miR-204 could help treat MYCN-amplified neuroblastoma. In neuroblastoma patients, low tumor levels of miR-204 correlated with high...
07:00 , Sep 26, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes v-Maf musculoaponeurotic fibrosarcoma oncogene homolog A (MAFA; RIPE3b1); microRNA-204 (miR-204) Mouse and cell culture studies suggest inhibiting miR-204 could...
08:00 , Mar 10, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease Hypertension MicroRNA-204 (miR-204) In vitro and rodent studies suggest that re-establishing miR-204 expression could help treat pulmonary arterial hypertension (PAH). In PAH patients...
07:00 , Mar 13, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myeloid leukemia (AML) miR-204; nucleophosmin (NPM1) An in vitro study suggests that microRNA signatures could be a useful diagnostic for...